This clinical trial is focused on studying a condition known as Heart Failure with Preserved Ejection Fraction (HFpEF). This is a type of heart failure where the heart muscle contracts normally but the ventricles do not relax as they should during heartbeats. The trial will evaluate a new treatment called BMS-986435/MYK-224, which is being developed to help manage this condition. Participants in the study will receive either the new treatment or a placebo, which is a substance with no active medication.

The purpose of the study is to understand the safety and tolerability of MYK-224 in individuals with HFpEF. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. Participants will take the medication in the form of a tablet, which is taken orally. The study will monitor the number of side effects experienced by participants and measure the amount of the drug in the bloodstream to gather important information about how the body processes the medication.

The trial is expected to run until early 2025, with recruitment starting in 2024. This study aims to provide valuable insights into the potential benefits and risks of using MYK-224 for treating HFpEF, ultimately contributing to better management of this heart condition. Participants will be closely monitored throughout the study to ensure their safety and to collect data that will help researchers understand the effects of the treatment.